Early onset of cannabis use and violent behavior in psychosis.


Journal

European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820

Informations de publication

Date de publication:
16 07 2020
Historique:
pubmed: 17 7 2020
medline: 31 3 2021
entrez: 17 7 2020
Statut: epublish

Résumé

Although evidence from psychosis patients demonstrates the adverse effects of cannabis use (CU) at a young age and that the rate of CU is high in subgroups of young violent patients with psychotic disorders, little is known about the possible effect of the age of onset of CU on later violent behaviors (VB). So, we aimed to explore the impact of age at onset of CU on the risk of displaying VB in a cohort of early psychosis patients. Data were collected prospectively over a 36-month period in the context of an early psychosis cohort study. A total of 265 patients, aged 18-35 years, were included in the study. Logistic regression was performed to assess the link between age of onset of substance use and VB. Among the 265 patients, 72 had displayed VB and 193 had not. While violent patients began using cannabis on average at age 15.29 (0.45), nonviolent patients had started on average at age 16.97 (0.35) (p = 0.004). Early-onset CU (up to age 15) was a risk factor for VB (odds ratio = 4.47, confidence interval [CI]: 1.13-20.06) when the model was adjusted for age group, other types of substance use, being a user or a nonuser and various violence risk factors and covariates. History of violence and early CU (until 15) were the two main risk factors for VB. Our results suggest that early-onset CU may play a role in the emergence of VB in early psychosis.

Sections du résumé

BACKGROUND
Although evidence from psychosis patients demonstrates the adverse effects of cannabis use (CU) at a young age and that the rate of CU is high in subgroups of young violent patients with psychotic disorders, little is known about the possible effect of the age of onset of CU on later violent behaviors (VB). So, we aimed to explore the impact of age at onset of CU on the risk of displaying VB in a cohort of early psychosis patients.
METHOD
Data were collected prospectively over a 36-month period in the context of an early psychosis cohort study. A total of 265 patients, aged 18-35 years, were included in the study. Logistic regression was performed to assess the link between age of onset of substance use and VB.
RESULTS
Among the 265 patients, 72 had displayed VB and 193 had not. While violent patients began using cannabis on average at age 15.29 (0.45), nonviolent patients had started on average at age 16.97 (0.35) (p = 0.004). Early-onset CU (up to age 15) was a risk factor for VB (odds ratio = 4.47, confidence interval [CI]: 1.13-20.06) when the model was adjusted for age group, other types of substance use, being a user or a nonuser and various violence risk factors and covariates. History of violence and early CU (until 15) were the two main risk factors for VB.
CONCLUSIONS
Our results suggest that early-onset CU may play a role in the emergence of VB in early psychosis.

Identifiants

pubmed: 32669157
doi: 10.1192/j.eurpsy.2020.71
pii: S0924933820000711
pmc: PMC7503178
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e78

Références

Front Psychiatry. 2018 Jul 04;9:294
pubmed: 30022956
Aust N Z J Psychiatry. 2004 Apr;38(4):254-9
pubmed: 15038805
Rev Med Suisse Romande. 2004 Apr;124(4):221-4
pubmed: 15209055
Nord J Psychiatry. 2018 Nov;72(8):561-571
pubmed: 30099913
Schizophr Bull. 1990;16(1):57-67
pubmed: 2333482
Early Interv Psychiatry. 2013 Aug;7(3):322-8
pubmed: 23445318
Am J Psychiatry. 2014 Sep;171(9):939-48
pubmed: 25073506
Law Hum Behav. 2008 Jun;32(3):228-40
pubmed: 17602288
Schizophr Bull. 2005 Jul;31(3):608-12
pubmed: 15976013
Schizophr Bull. 2014 Nov;40(6):1509-17
pubmed: 24345517
Psychol Med. 2008 Jul;38(7):975-87
pubmed: 17988416
Acta Psychiatr Scand. 2005 Aug;112(2):141-8
pubmed: 15992396
Schizophr Res. 2011 Aug;130(1-3):234-7
pubmed: 21441016
J Drug Educ. 2011;41(4):369-89
pubmed: 22455101
BMJ. 2002 Nov 23;325(7374):1212-3
pubmed: 12446537
Schizophr Bull. 2017 Sep 1;43(5):1021-1026
pubmed: 28605537
Arch Gen Psychiatry. 2000 Oct;57(10):979-86
pubmed: 11015816
Schizophr Res. 2014 Jul;156(2-3):272-6
pubmed: 24837683
Schizophr Bull. 2011 Sep;37(5):921-9
pubmed: 21562140
Front Psychiatry. 2017 Sep 21;8:176
pubmed: 28983261
Curr Pharm Des. 2012;18(32):5070-80
pubmed: 22716152
Drug Alcohol Depend. 2018 Oct 1;191:234-258
pubmed: 30153606
Schizophr Res. 2005 Nov 15;79(2-3):289-95
pubmed: 16125368
Australas Psychiatry. 2017 Feb;25(1):28-31
pubmed: 27679634
PLoS One. 2013;8(2):e55942
pubmed: 23418482
Psychiatry Res. 2018 Oct;268:381-387
pubmed: 30121541
Aust N Z J Psychiatry. 2016 Mar;50(3):208-19
pubmed: 26286531
Acta Psychiatr Scand. 2013 Dec;128(6):413-21
pubmed: 23521361
Acta Psychiatr Scand. 2008 Sep;118(3):209-13
pubmed: 18452569
Psychol Med. 2011 Jun;41(6):1301-10
pubmed: 20925969
JAMA Psychiatry. 2019 Jul 1;76(7):708-720
pubmed: 30865282
Neurosci Biobehav Rev. 2011 Aug;35(8):1779-87
pubmed: 21530584
Can J Psychiatry. 2010 Mar;55(3):165-71
pubmed: 20370967
Schizophr Res. 2005 Jan 1;72(2-3):161-8
pubmed: 15560961
Lancet Psychiatry. 2016 Mar;3(3):215-25
pubmed: 26777297
Aust N Z J Psychiatry. 2010 Jan;44(1):85-93
pubmed: 20073570
Early Interv Psychiatry. 2018 Jun;12(3):400-409
pubmed: 27136461
Front Psychiatry. 2013 Sep 03;4:97
pubmed: 24027539
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Psychiatry Res. 2019 Apr;274:42-48
pubmed: 30780061
Early Interv Psychiatry. 2019 Jun;13(3):517-524
pubmed: 29143486
JAMA Psychiatry. 2019 Apr 1;76(4):426-434
pubmed: 30758486
Psychiatry Res. 2009 Jul 15;173(1):39-44
pubmed: 19442493
Aust N Z J Psychiatry. 2014 Jan;48(1):94-5
pubmed: 23661783
Med J Aust. 2007 Mar 19;186(6):301-4
pubmed: 17371211
Int J Law Psychiatry. 2010 May-Jun;33(3):171-6
pubmed: 20546896
Eur Psychiatry. 2018 Mar;49:30-36
pubmed: 29353178
Psychol Med. 2019 Aug 29;:1-6
pubmed: 31462346
Arch Gen Psychiatry. 2011 Jun;68(6):555-61
pubmed: 21300939
Schizophr Res. 2018 Apr;194:4-12
pubmed: 28697856
Early Interv Psychiatry. 2019 Aug;13(4):832-840
pubmed: 29740953
Br J Psychiatry. 2001 May;178:433-40
pubmed: 11331559
Psychol Med. 2016 Jun;46(8):1663-77
pubmed: 26961342
Schizophr Res. 2011 Feb;125(2-3):209-20
pubmed: 21208783
Schizophr Bull. 2010 Nov;36(6):1115-30
pubmed: 19386576
Psychol Med. 2015 Oct;45(13):2727-36
pubmed: 26350397
Can J Psychiatry. 2018 Jul;63(7):457-464
pubmed: 29682999
Science. 1999 Mar 19;283(5409):1908-11
pubmed: 10082463
Riv Psichiatr. 2013 Jan-Feb;48(1):43-50
pubmed: 23438700

Auteurs

Valerie Moulin (V)

Department of Psychiatry, Unit for Research in Legal Psychiatry and Psychology, Institute of Forensic Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Luis Alameda (L)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Department of Psychiatry, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain.
Instituto de Investigacion Sanitaria de Sevilla, IBiS, Sevilla, Spain.

David Framorando (D)

Department of Psychiatry, Unit for Research in Legal Psychiatry and Psychology, Institute of Forensic Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Philipp-S Baumann (PS)

Department of Psychiatry, Service of General Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Mehdi Gholam (M)

Department of Psychiatry, Center for Psychiatric Epidemiology and Psychopathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Jacques Gasser (J)

Department of Psychiatry, Unit for Research in Legal Psychiatry and Psychology, Institute of Forensic Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Kim-Q Do Cuenod (KQ)

Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Philippe Conus (P)

Department of Psychiatry, Service of General Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH